XML 98 R83.htm IDEA: XBRL DOCUMENT v3.10.0.1

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions, $ in Millions, $ in Millions					1 Months Ended								12 Months Ended
	Oct. 04, 2018 USD ($)	Jun. 27, 2018 USD ($)	Aug. 21, 2017 USD ($)	Jul. 15, 2015 USD ($)	Nov. 30, 2017 USD ($)	Jul. 31, 2015 USD ($)	Sep. 30, 2013 USD ($)	Apr. 30, 2013 USD ($)	Aug. 31, 2012 USD ($)	Dec. 31, 2010 USD ($)	Nov. 30, 2009 USD ($)	Aug. 31, 2008 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2014 CAD ($)	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 CAD ($)	Dec. 31, 2016 USD ($)	May 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Mar. 31, 2014 USD ($)	Nov. 30, 2013 USD ($)	Aug. 31, 2013 USD ($)	Jan. 31, 2009 USD ($)	Jul. 31, 2008 USD ($)	Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items]
Damages assessment													$ 235.5
Sales														$ 94
Sales					$ 459.0
Sales					$ 1,300.0
Modafinil payment																		$ 1,200.0
Modafinil Euro sales | €															€ 46.5
Annual sales at the time of settlement																							$ 350.0
Annual sales of Effexor			$ 2,600.0
Annual sales of Lamictal																								$ 2,300.0	$ 950.0
Annual sales of Niaspan							$ 1,100.0	$ 416.0
Annual sales of Lidoderm							$ 1,400.0														$ 1,200.0
Annual sales of Aggrenox				$ 455.0								$ 340.0
Annual sales of Actos									$ 2,800.0	$ 3,700.0
Annual sales of Acto plus									$ 430.0	$ 500.0
Annual sales of Namenda						$ 550.0					$ 1,100.0
Annual sales of Intuniv																	$ 335.0		$ 327.0
Compensatory damages and penalties																						$ 12.4
Punitive damages																				$ 17.9
Litigation settlement amount	$ 135.0
Loss contingency payment													22.0
Eosinophilic Esophagitis [Member]
Commitment And Contingencies [Line Items]
Damage claimed													200.0
Eosinophilic Esophagitis [Member] | United States [Member]
Commitment And Contingencies [Line Items]
Damage claimed													150.0
Eosinophilic Esophagitis [Member] | Europe [Member]
Commitment And Contingencies [Line Items]
Damage claimed													50.0
AbbVie [Member]
Commitment And Contingencies [Line Items]
Legal fees													$ 448,000.0
Janssen and Millennium [Member]
Commitment And Contingencies [Line Items]
Maximum damages payable																$ 200
Litigation settlement awarded from other party		$ 5.0
AndroGel Rate at 1% [Member]
Commitment And Contingencies [Line Items]
Annual sales at the time of settlement																							$ 140.0

X

- Definition

Annual sales at time of settlement.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Annual sales of Acto plus.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfActoplus
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Actos.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfActos
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Aggrenox.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfAggrenox
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Aloxi.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfAloxi
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of effexor.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfEffexor
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Intuniv.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfIntuniv
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Annual sales of Lamictal.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfLamictal
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Annual sales of Lidoderm.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfLidoderm
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Annual sales of Namenda.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfNamenda
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Niaspan.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfNiaspan
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual Sales Of Velcade

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfVelcade
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual Sales of Zytiga

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfZytiga
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Commitment And Contingencies [Line Items]

+ References

No definition available.

+ Details

Name:	teva_CommitmentAndContingenciesLineItems
Namespace Prefix:	teva_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Compensatory damages and penalties.

+ References

No definition available.

+ Details

Name:	teva_CompensatoryDamagesAndPenalties
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Damages assessment.

+ References

No definition available.

+ Details

Name:	teva_DamagesAssessment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Modafinil Euro sales.

+ References

No definition available.

+ Details

Name:	teva_ModafinilEuroSales
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Modafinil payment.

+ References

No definition available.

+ Details

Name:	teva_ModafinilPayment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Punitive damages.

+ References

No definition available.

+ Details

Name:	teva_PunitiveDamages
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_LegalFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of damages paid to the plaintiff in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248

+ Details

Name:	us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=teva_AbbVieMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: